NCT04767308 2021-02-23
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Huazhong University of Science and Technology
Phase EARLY_PHASE1 Unknown
Clinical Trials
4 trialsNCT04665063 2020-12-29
A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT04666168 2020-12-14
A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT04610125 2020-10-30
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown